Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Genmab ( (GMAB) ) is now available.
On July 16, 2025, Genmab A/S announced that the net sales of DARZALEX® (daratumumab) for the second quarter of 2025 reached USD 3,539 million. The sales were divided between USD 2,017 million in the U.S. and USD 1,521 million in the rest of the world. Genmab receives royalties from Johnson & Johnson on these sales, reflecting the company’s strong position in the biotechnology industry and its successful collaboration with J&J.
The most recent analyst rating on (GMAB) stock is a Hold with a $31.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
Spark’s Take on GMAB Stock
According to Spark, TipRanks’ AI Analyst, GMAB is a Outperform.
Genmab’s strong financial performance is the primary driver of its stock score, reflecting solid profitability and financial stability. Valuation is favorable with a low P/E ratio, but technical analysis indicates mixed momentum signals. The absence of a dividend yield and lack of recent earnings call insights are secondary factors.
To see Spark’s full report on GMAB stock, click here.
More about Genmab
Genmab is an international biotechnology company headquartered in Copenhagen, Denmark, with a focus on developing innovative antibody therapeutics. Established in 1999, the company has a proprietary pipeline that includes bispecific T-cell engagers, antibody-drug conjugates, and next-generation immune checkpoint modulators. Genmab’s vision is to transform the lives of people with cancer and other serious diseases by 2030.
Average Trading Volume: 1,424,960
Technical Sentiment Signal: Sell
Current Market Cap: $13.13B
For detailed information about GMAB stock, go to TipRanks’ Stock Analysis page.